Celator Pharmaceuticals, Inc. Announces Business Update and Fiscal Second Quarter 2013 Operational and Financial Results  
8/15/2013 7:06:30 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today reported second quarter 2013 financial results.

“Celator continued to execute against key clinical and corporate milestones in the second quarter. Most importantly, with the funding provided by our last private placement financing and support from The Leukemia & Lymphoma Society® (LLS), we are making excellent progress in our Phase 3 clinical study of CPX-351 in secondary AML, which is enrolling on schedule,” said Scott Jackson, chief executive officer of Celator.

Hey, check out all the research scientist jobs. Post your resume today!